Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30433867 | 1.00 | MAP3K5 (0.53) | MAP3K5MAP3K6 | |
| SCHEMBL28653758 | 0.86 | MAP3K5 (0.39) | MAP3K5MAP3K6 | |
| SCHEMBL25619915 | 0.85 | MAP3K5 (0.40) | MAP3K5MAP3K6 | |
| SCHEMBL18027905 | 0.84 | MAP3K5 (0.55) | MAP3K5MAP3K6 | |
| SCHEMBL20557509 | 0.83 | MAP3K5 (0.46) | MAP3K5MAP3K6 | |
| SCHEMBL20557175 | 0.83 | MAP3K5 (0.46) | MAP3K5MAP3K6 | |
| SCHEMBL30433991 | 0.83 | MAP3K5 (0.46) | MAP3K5MAP3K6 | |
| SCHEMBL30433342 | 0.83 | MAP3K5 (0.46) | MAP3K5MAP3K6 | |
| SCHEMBL22642547 | 0.81 | MAP3K5 (0.51) | MAP3K5MAP3K6 | |
| SCHEMBL28391289 | 0.81 | MAP3K5 (0.53) | MAP3K5MAP3K6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552777-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20240376079-A1 | Apoptosis Signal-Regulating Kinase 1 Inhibitors and Methods of Use Thereof | ENANTA PHARM INC (US) | 2024-11-14 | — | — | US | disclosed |
| US-12018017-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3621615-B1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230174515-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174515-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2023-06-08 | — | — | US | disclosed |
| CN-110869017-B | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | 英安塔制药有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-11560368-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20220356167-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2022-11-10 | — | — | US | disclosed |
| US-10988458-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200331890-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | SILICON VALLEY BANK | 2020-10-22 | — | — | US | disclosed |
| US-10683279-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10683279-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| CN-110869017-A | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | 英安塔制药有限公司 | 2020-03-06 | — | — | CN | disclosed |
| US-20180327388-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552777-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | AIFM1, BAD, IRAK1 | MAP3K5 81/4885MAP3K6 80/4885 |
| US-20240376079-A1 | Apoptosis Signal-Regulating Kinase 1 Inhibitors and Methods of Use Thereof | BAD, CASP1, BAX | MAP3K5 23/4885MAP3K6 19/4885 |
| US-11560368-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, CASP1, BAX | MAP3K5 23/4885MAP3K6 19/4885 |
| US-12018017-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, CASP1, BAX | MAP3K5 23/4885MAP3K6 19/4885 |
| US-10988458-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, CASP1, BAX | MAP3K5 23/4885MAP3K6 19/4885 |
| US-20180327388-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | BAD, CASP1, BAX | MAP3K5 23/4885MAP3K6 19/4885 |
| US-20220356167-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | BAD, CASP1, BAX | MAP3K5 23/4885MAP3K6 19/4885 |
| US-20200331890-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | BAD, CASP1, BAX | MAP3K5 23/4885MAP3K6 19/4885 |
| US-10683279-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, CASP1, BAX | MAP3K5 23/4885MAP3K6 19/4885 |
| US-20230174515-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | BAD, CASP1, BAX | MAP3K5 23/4885MAP3K6 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.